Abstract

  We herein report the preliminary results of regimen with 45.5 Gy/7 fractions using high-dose rate (HDR) brachytherapy as monotherapy for localized prostate cancer. Between Jan. 2005 and Dec. 2011, 73 patients were treated with HDR in 45.5 Gy/7 fractions. Five patients developed PSA recurrence, and 3-year and 5-year PSA recurrence-free survival rate was 95% and 96% respectively. Two patients developed clinical recurrence, and 3-year and 5-year clinical recurrence-free survival rate was 98% and 96% respectively. Grade 2 acute and late toxicities occurred in 7 (9.6%) and 9 (12.3%) patients. From these results, HDR brachytherapy with 45.5 Gy/7 fractions might be effective and safe treatment for localized prostate cancer.